乳腺癌组织uPA和PAI-1表达与临床病理因素相关性的探讨

目的:探讨尿激酶型纤溶酶原激活物(uPA)、纤溶酶原激活物抑制因子-1(PAI-1)在乳腺癌组织中的表达及其临床意义.方法:免疫组化SP法检测乳腺癌组织及良性乳腺疾病组织中uPA、PAI-1的表达,结合临床病理因素、骨髓微转移状况及随访结果对数据进行统计处理.结果:50例乳腺癌患者癌组织中uPA、PAI-1表达阳性率分别为92.0%和82.0%.与良性乳腺疾病相比,癌组织中两者表达增强,P值均为0.001.癌组织中uPA、PAI-1表达随肿瘤的增大而增高;淋巴结转移阳性者表达强度高;临床分期晚者表达强度高;组织学分级高者表达强度高.ER、PR表达阴性组uPA、PAI-1表达强度较阳性组高,P值均<0.05;c-erbB-2蛋白过表达组uPA、PAI-1表达强度高,P值分别为0.021和0.014; uPA、PAI-1表达强度高者易发生骨髓微转移,且易发生远处转移.uPA与PAI-1的表达呈正相关,r=0.664, P=0.000.结论:乳腺癌组织uPA、PAI-1高表达者发生骨髓微转移及远处转移机会高、预后差,uPA、PAI-1检测可以作为判断乳腺癌预后的指标之一.uPA与PAI-1两者之间存在协同作用.

Relationship between uPA/PAI-1 and clinical pathology factors in breast cancer tissues

OBJECTIVE:To investigate the expressions of uPA and PAI-1,and their clinical significance.METHODS: By immunohistochemistry,uPA and PAI-1 in breast cancer tissues and breast tissues of benign diseases as the controls were detected,the results to the clinical pathology factors and the follow-up were combined,then the data were analyzed statistically.RESULTS: About 92.0% of positive expression of uPA in the malignant group was found,while the condition of PAI-1 was that about 82.0% of positive expression of PA...